Amarin Corp Plc (AMRN)

[sts66]

Unfscking believable! They're basically repeating ANCHOR!

Detailed Description:

Metabolic Actions of Omega-3 Fatty Acids on Inflammation and Adipocyte Lipolysis in the Metabolic Syndrome

Epidemiological studies identify metabolic syndrome (MetS) as a biomarker of cardiovascular disease (CVD) risk, and recent AHA scientific statements recommend intensive lifestyle diet and exercise measures to reduce risk. Marine-derived omega-3 polyunsaturated fatty acids such as, eicosapentanoic acid (EPA) improve many constituents of the metabolic syndrome such as lowering fasting TG and glucose levels, inflammation, insulin resistance and blood pressure.


Arms Assigned Interventions Experimental: EPA (marine fatty acids)
Subjects will receive EPA , four 1 gram capsules daily. Dietary Supplement: EPA (marine fatty acids) Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.

Placebo Comparator:
Placebo Subjects will be randomized to receive placebo, four 1 gram capsules daily. Dietary Supplement: Placebo Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.

Are they using Vascepa? And wonder what placebo is - mineral oil I'll bet!